{"id":"W2602605464","doi":"10.1182/blood-2017-01-761973","title":"Venetoclax and obinutuzumab in chronic lymphocytic leukemia","year":2017,"lang":"en","type":"letter","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":117,"is_retracted":false,"has_abstract":true,"ca_institutions":"Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Venetoclax; Obinutuzumab; Chronic lymphocytic leukemia; Chlorambucil; Medicine; Internal medicine; Fludarabine; Ibrutinib; Leukemia; IGHV@; Oncology; Bendamustine; Immunology; Chemotherapy; Cyclophosphamide","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0003328188,0.0005822615,0.001189983,0.0004504616,0.0001393204,0.0001425315,0.0005911036,0.001589241,0.0001676009],"category_scores_gemma":[0.0003071134,0.0005436093,0.0001924751,0.0001604391,0.0004637653,0.0001075691,0.0004055041,0.002397022,0.0003320886],"about_ca_system_candidate":true,"about_ca_system_consensus":true,"about_ca_system_score_codex":0.4332169,"about_ca_system_score_gemma":0.2614121,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.007007636,"about_ca_topic_score_gemma":0.000198828,"domain_scores_codex":[0.9962009,0.00009676265,0.0005371397,0.001046758,0.0009087705,0.001209672],"domain_scores_gemma":[0.9972731,0.0002378975,0.0002347484,0.001941055,0.0000911165,0.0002220181],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001888644,0.00003103073,0.0001154228,0.006473708,0.0006709286,0.074545,0.0002329968,0.00007473684,0.0005577935,0.00001667625,0.9142048,0.002888039],"study_design_scores_gemma":[0.1091016,0.0006371606,0.0004132671,0.003375032,0.0008059202,0.009827473,0.00001073179,0.01016509,0.001397929,0.0001784984,0.8631487,0.0009385984],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8716228,0.03696387,0.000004169349,0.05063655,0.00105962,0.004850705,0.0001276825,0.0004568586,0.03427772],"genre_scores_gemma":[0.56792,0.008546868,0.0006086742,0.2800823,0.039074,0.001182124,0.001690328,0.00119522,0.09970046],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3037028,"threshold_uncertainty_score":0.9999045,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02331277208653235,"score_gpt":0.2935193183196323,"score_spread":0.2702065462331,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}